arrow_back Back to App

Increased Transparency in Foreign Drug Manufacturing: Safer Medicines for USA

This act aims to enhance the safety of medicines available in the USA by improving oversight of foreign manufacturers. It means that companies producing drug ingredients abroad will need to report their data more frequently, helping to detect issues faster and ensuring the medicines you take are safe and effective.
Key points
Foreign manufacturers of drug ingredients will be required to report information about their facilities and products more frequently.
Pharmaceutical companies must confirm they know all drug manufacturing locations and inform foreign suppliers of their obligations.
Reports on drug production amounts will be submitted quarterly instead of annually, improving market oversight.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_6483
Sponsor: Rep. Eshoo, Anna G. [D-CA-18]
Process start date: 2022-01-25
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Improved Transparency of Foreign Drug Manufacturing Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6483.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-01-25.

What are the main provisions?

Key points include:

  • Foreign manufacturers of drug ingredients will be required to report information about their facilities and products more frequently.
  • Pharmaceutical companies must confirm they know all drug manufacturing locations and inform foreign suppliers of their obligations.
  • Reports on drug production amounts will be submitted quarterly instead of annually, improving market oversight.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Eshoo, Anna G. [D-CA-18].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health